Clinical Trials Logo

Pyoderma Gangrenosum clinical trials

View clinical trials related to Pyoderma Gangrenosum.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04274166 Withdrawn - Clinical trials for Pyoderma Gangrenosum

Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum

Start date: May 2021
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to find out what effects (good and bad) secukinumab has on the subject and their pyoderma gangrenosum. Secukinumab is a type of medicine called human monoclonal antibodies. Monoclonal antibodies are proteins that recognize and attach to other specific proteins (in this case, immune system hormones called "cytokines") that your body produces. The cytokine (a "messenger" protein in the body) that secukinumab binds to and reduces the activity of is a naturally occurring cytokine called interleukin-17A (IL-17A). IL-17A is believed to be partly responsible for inflammation (pain, swelling, redness), and researchers believe that IL-17A may cause symptoms PG.

NCT ID: NCT00730717 Withdrawn - Clinical trials for Pyoderma Gangrenosum

Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum

Start date: May 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of Humira in the treatment of pyoderma gangrenosum.

NCT ID: NCT00690846 Withdrawn - Clinical trials for Pyoderma Gangrenosum

Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum

Start date: July 2007
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to see if Humira (adalimumab) is effective and safe in the treatment of pyoderma gangrenosum.